

# Global Cancer Drug based on PARP Inhibitor Market Research Report 2023

<https://marketpublishers.com/r/G92852892FE0EN.html>

Date: December 2023

Pages: 93

Price: US\$ 2,900.00 (Single User License)

ID: G92852892FE0EN

## Abstracts

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP)

According to QYResearch's new survey, global Cancer Drug based on PARP Inhibitor market is projected to reach US\$ 13040 million in 2029, increasing from US\$ 5904.1 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cancer Drug based on PARP Inhibitor market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

## Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cancer Drug based on PARP Inhibitor market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

## By Company

AstraZeneca

Merck & Co

GSK

Clovis Oncology

Pfizer

Zai Lab

## Segment by Type

Lynparza

Zejula

Rubraca

Talzenna

## Segment by Application

Ovarian Cancer

Breast Cancer

Other

## Consumption by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

The Cancer Drug based on PARP Inhibitor report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Manufacturers' Competition Patterns

Chapter 3: Country Level Sales Analysis

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6: Manufacturers' Outline

Chapter 7: Industry Chain, Market Channel and Customer Analysis

Chapter 8: Market Opportunities and Challenges

Chapter 9: Market Conclusions

Chapter 10: Research Methodology and Data Source

## Contents

### **1 CANCER DRUG BASED ON PARP INHIBITOR MARKET OVERVIEW**

- 1.1 Product Overview and Scope of Cancer Drug based on PARP Inhibitor
- 1.2 Cancer Drug based on PARP Inhibitor Segment by Type
  - 1.2.1 Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Type (2023-2029)
  - 1.2.2 Lynparza
  - 1.2.3 Zejula
  - 1.2.4 Rubraca
  - 1.2.5 Talzenna
- 1.3 Cancer Drug based on PARP Inhibitor Segment by Application
  - 1.3.1 Global Cancer Drug based on PARP Inhibitor Market Value by Application: (2023-2029)
  - 1.3.2 Ovarian Cancer
  - 1.3.3 Breast Cancer
  - 1.3.4 Other
- 1.4 Global Cancer Drug based on PARP Inhibitor Market Size Estimates and Forecasts
  - 1.4.1 Global Cancer Drug based on PARP Inhibitor Revenue 2018-2029
  - 1.4.2 Global Cancer Drug based on PARP Inhibitor Sales 2018-2029
  - 1.4.3 Global Cancer Drug based on PARP Inhibitor Market Average Price (2018-2029)
- 1.5 Assumptions and Limitations

### **2 CANCER DRUG BASED ON PARP INHIBITOR MARKET COMPETITION BY MANUFACTURERS**

- 2.1 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2018-2023)
- 2.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2018-2023)
- 2.3 Global Cancer Drug based on PARP Inhibitor Average Price by Manufacturers (2018-2023)
- 2.4 Global Cancer Drug based on PARP Inhibitor Industry Ranking 2021 VS 2022 VS 2023
- 2.5 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Manufacturing Sites & Headquarters
- 2.6 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Product Type & Application

## 2.7 Cancer Drug based on PARP Inhibitor Market Competitive Situation and Trends

### 2.7.1 Cancer Drug based on PARP Inhibitor Market Concentration Rate

### 2.7.2 The Global Top 5 and Top 10 Largest Cancer Drug based on PARP Inhibitor Players Market Share by Revenue

### 2.7.3 Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

## 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

## **3 CANCER DRUG BASED ON PARP INHIBITOR RETROSPECTIVE MARKET SCENARIO BY REGION**

### 3.1 Global Cancer Drug based on PARP Inhibitor Market Size by Region: 2018 Versus 2022 Versus 2029

### 3.2 Global Cancer Drug based on PARP Inhibitor Global Cancer Drug based on PARP Inhibitor Sales by Region: 2018-2029

#### 3.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2018-2023

#### 3.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2024-2029

### 3.3 Global Cancer Drug based on PARP Inhibitor Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2018-2029

#### 3.3.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2018-2023

#### 3.3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2024-2029

### 3.4 North America Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country

#### 3.4.1 North America Cancer Drug based on PARP Inhibitor Market Size by Country: 2018 VS 2022 VS 2029

#### 3.4.2 North America Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)

#### 3.4.3 North America Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)

##### 3.4.4 United States

##### 3.4.5 Canada

### 3.5 Europe Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country

#### 3.5.1 Europe Cancer Drug based on PARP Inhibitor Market Size by Country: 2018 VS 2022 VS 2029

#### 3.5.2 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)

#### 3.5.3 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)

##### 3.5.4 Germany

##### 3.5.5 France

##### 3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country

3.6.1 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)

3.6.3 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country

3.7.1 Latin America Cancer Drug based on PARP Inhibitor Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)

3.7.3 Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Facts & Figures by Country

3.8.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)

3.8.3 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)

3.8.4 Turkey



3.8.5 Saudi Arabia

3.8.6 UAE

## **4 SEGMENT BY TYPE**

4.1 Global Cancer Drug based on PARP Inhibitor Sales by Type (2018-2029)

4.1.1 Global Cancer Drug based on PARP Inhibitor Sales by Type (2018-2023)

4.1.2 Global Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029)

4.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)

4.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2029)

4.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2023)

4.2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029)

4.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)

4.3 Global Cancer Drug based on PARP Inhibitor Price by Type (2018-2029)

## **5 SEGMENT BY APPLICATION**

5.1 Global Cancer Drug based on PARP Inhibitor Sales by Application (2018-2029)

5.1.1 Global Cancer Drug based on PARP Inhibitor Sales by Application (2018-2023)

5.1.2 Global Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029)

5.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)

5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2029)

5.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2023)

5.2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029)

5.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)

5.3 Global Cancer Drug based on PARP Inhibitor Price by Application (2018-2029)

## **6 KEY COMPANIES PROFILED**

6.1 AstraZeneca

6.1.1 AstraZeneca Corporation Information

6.1.2 AstraZeneca Description and Business Overview

6.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross

## Margin (2018-2023)

6.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio

6.1.5 AstraZeneca Recent Developments/Updates

## 6.2 Merck & Co

6.2.1 Merck & Co Corporation Information

6.2.2 Merck & Co Description and Business Overview

6.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross

## Margin (2018-2023)

6.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio

6.2.5 Merck & Co Recent Developments/Updates

## 6.3 GSK

6.3.1 GSK Corporation Information

6.3.2 GSK Description and Business Overview

6.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin

## (2018-2023)

6.3.4 GSK Cancer Drug based on PARP Inhibitor Product Portfolio

6.3.5 GSK Recent Developments/Updates

## 6.4 Clovis Oncology

6.4.1 Clovis Oncology Corporation Information

6.4.2 Clovis Oncology Description and Business Overview

6.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Revenue and

## Gross Margin (2018-2023)

6.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio

6.4.5 Clovis Oncology Recent Developments/Updates

## 6.5 Pfizer

6.5.1 Pfizer Corporation Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross Margin

## (2018-2023)

6.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

## 6.6 Zai Lab

6.6.1 Zai Lab Corporation Information

6.6.2 Zai Lab Description and Business Overview

6.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Revenue and Gross

## Margin (2018-2023)

6.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio

6.6.5 Zai Lab Recent Developments/Updates

## **7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS**

- 7.1 Cancer Drug based on PARP Inhibitor Industry Chain Analysis
- 7.2 Cancer Drug based on PARP Inhibitor Key Raw Materials
  - 7.2.1 Key Raw Materials
  - 7.2.2 Raw Materials Key Suppliers
- 7.3 Cancer Drug based on PARP Inhibitor Production Mode & Process
- 7.4 Cancer Drug based on PARP Inhibitor Sales and Marketing
  - 7.4.1 Cancer Drug based on PARP Inhibitor Sales Channels
  - 7.4.2 Cancer Drug based on PARP Inhibitor Distributors
- 7.5 Cancer Drug based on PARP Inhibitor Customers

## **8 CANCER DRUG BASED ON PARP INHIBITOR MARKET DYNAMICS**

- 8.1 Cancer Drug based on PARP Inhibitor Industry Trends
- 8.2 Cancer Drug based on PARP Inhibitor Market Drivers
- 8.3 Cancer Drug based on PARP Inhibitor Market Challenges
- 8.4 Cancer Drug based on PARP Inhibitor Market Restraints

## **9 RESEARCH FINDING AND CONCLUSION**

## **10 METHODOLOGY AND DATA SOURCE**

- 10.1 Methodology/Research Approach
  - 10.1.1 Research Programs/Design
  - 10.1.2 Market Size Estimation
  - 10.1.3 Market Breakdown and Data Triangulation
- 10.2 Data Source
  - 10.2.1 Secondary Sources
  - 10.2.2 Primary Sources
- 10.3 Author List
- 10.4 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Type (2023-2029) & (US\$ Million)

Table 2. Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Application (2023-2029) & (US\$ Million)

Table 3. Global Cancer Drug based on PARP Inhibitor Market Competitive Situation by Manufacturers in 2022

Table 4. Global Cancer Drug based on PARP Inhibitor Sales (K Units) of Key Manufacturers (2018-2023)

Table 5. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2018-2023)

Table 6. Global Cancer Drug based on PARP Inhibitor Revenue (US\$ Million) by Manufacturers (2018-2023)

Table 7. Global Cancer Drug based on PARP Inhibitor Revenue Share by Manufacturers (2018-2023)

Table 8. Global Market Cancer Drug based on PARP Inhibitor Average Price (US\$/Unit) of Key Manufacturers (2018-2023)

Table 9. Global Key Players of Cancer Drug based on PARP Inhibitor, Industry Ranking, 2021 VS 2022 VS 2023

Table 10. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Product Type & Application

Table 12. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Cancer Drug based on PARP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug based on PARP Inhibitor as of 2022)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Cancer Drug based on PARP Inhibitor Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 17. Global Cancer Drug based on PARP Inhibitor Sales by Region (2018-2023) & (K Units)

Table 18. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2018-2023)

Table 19. Global Cancer Drug based on PARP Inhibitor Sales by Region (2024-2029) & (K Units)

Table 20. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2024-2029)

Table 21. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2023) & (US\$ Million)

Table 22. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2018-2023)

Table 23. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2024-2029) & (US\$ Million)

Table 24. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2024-2029)

Table 25. North America Cancer Drug based on PARP Inhibitor Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 26. North America Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023) & (K Units)

Table 27. North America Cancer Drug based on PARP Inhibitor Sales by Country (2024-2029) & (K Units)

Table 28. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023) & (US\$ Million)

Table 29. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2024-2029) & (US\$ Million)

Table 30. Europe Cancer Drug based on PARP Inhibitor Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023) & (K Units)

Table 32. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2024-2029) & (K Units)

Table 33. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023) & (US\$ Million)

Table 34. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2024-2029) & (US\$ Million)

Table 35. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region: 2018 VS 2022 VS 2029 (US\$ Million)

Table 36. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2018-2023) & (K Units)

Table 37. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2024-2029) & (K Units)

Table 38. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region

(2018-2023) & (US\$ Million)

Table 39. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region

(2024-2029) & (US\$ Million)

Table 40. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country:

2018 VS 2022 VS 2029 (US\$ Million)

Table 41. Latin America Cancer Drug based on PARP Inhibitor Sales by Country

(2018-2023) & (K Units)

Table 42. Latin America Cancer Drug based on PARP Inhibitor Sales by Country

(2024-2029) & (K Units)

Table 43. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country

(2018-2023) & (US\$ Million)

Table 44. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country

(2024-2029) & (US\$ Million)

Table 45. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by

Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 46. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Country

(2018-2023) & (K Units)

Table 47. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Country

(2024-2029) & (K Units)

Table 48. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by

Country (2018-2023) & (US\$ Million)

Table 49. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by

Country (2024-2029) & (US\$ Million)

Table 50. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Type

(2018-2023)

Table 51. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Type

(2024-2029)

Table 52. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type

(2018-2023)

Table 53. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type

(2024-2029)

Table 54. Global Cancer Drug based on PARP Inhibitor Revenue (US\$ Million) by Type

(2018-2023)

Table 55. Global Cancer Drug based on PARP Inhibitor Revenue (US\$ Million) by Type

(2024-2029)

Table 56. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type

(2018-2023)

Table 57. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type

(2024-2029)

Table 58. Global Cancer Drug based on PARP Inhibitor Price (US\$/Unit) by Type (2018-2023)

Table 59. Global Cancer Drug based on PARP Inhibitor Price (US\$/Unit) by Type (2024-2029)

Table 60. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Application (2018-2023)

Table 61. Global Cancer Drug based on PARP Inhibitor Sales (K Units) by Application (2024-2029)

Table 62. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2023)

Table 63. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2024-2029)

Table 64. Global Cancer Drug based on PARP Inhibitor Revenue (US\$ Million) by Application (2018-2023)

Table 65. Global Cancer Drug based on PARP Inhibitor Revenue (US\$ Million) by Application (2024-2029)

Table 66. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2023)

Table 67. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2024-2029)

Table 68. Global Cancer Drug based on PARP Inhibitor Price (US\$/Unit) by Application (2018-2023)

Table 69. Global Cancer Drug based on PARP Inhibitor Price (US\$/Unit) by Application (2024-2029)

Table 70. AstraZeneca Corporation Information

Table 71. AstraZeneca Description and Business Overview

Table 72. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 73. AstraZeneca Cancer Drug based on PARP Inhibitor Product

Table 74. AstraZeneca Recent Developments/Updates

Table 75. Merck & Co Corporation Information

Table 76. Merck & Co Description and Business Overview

Table 77. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 78. Merck & Co Cancer Drug based on PARP Inhibitor Product

Table 79. Merck & Co Recent Developments/Updates

Table 80. GSK Corporation Information

Table 81. GSK Description and Business Overview

Table 82. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US\$

Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 83. GSK Cancer Drug based on PARP Inhibitor Product

Table 84. GSK Recent Developments/Updates

Table 85. Clovis Oncology Corporation Information

Table 86. Clovis Oncology Description and Business Overview

Table 87. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Clovis Oncology Cancer Drug based on PARP Inhibitor Product

Table 89. Clovis Oncology Recent Developments/Updates

Table 90. Pfizer Corporation Information

Table 91. Pfizer Description and Business Overview

Table 92. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. Pfizer Cancer Drug based on PARP Inhibitor Product

Table 94. Pfizer Recent Developments/Updates

Table 95. Zai Lab Corporation Information

Table 96. Zai Lab Description and Business Overview

Table 97. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 98. Zai Lab Cancer Drug based on PARP Inhibitor Product

Table 99. Zai Lab Recent Developments/Updates

Table 100. Key Raw Materials Lists

Table 101. Raw Materials Key Suppliers Lists

Table 102. Cancer Drug based on PARP Inhibitor Distributors List

Table 103. Cancer Drug based on PARP Inhibitor Customers List

Table 104. Cancer Drug based on PARP Inhibitor Market Trends

Table 105. Cancer Drug based on PARP Inhibitor Market Drivers

Table 106. Cancer Drug based on PARP Inhibitor Market Challenges

Table 107. Cancer Drug based on PARP Inhibitor Market Restraints

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources



## List Of Figures

### LIST OF FIGURES

- Figure 1. Product Picture of Cancer Drug based on PARP Inhibitor
- Figure 2. Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Type (2023-2029) & (US\$ Million)
- Figure 3. Global Cancer Drug based on PARP Inhibitor Market Share by Type in 2022 & 2029
- Figure 4. Lynparza Product Picture
- Figure 5. Zejula Product Picture
- Figure 6. Rubraca Product Picture
- Figure 7. Talzenna Product Picture
- Figure 8. Global Cancer Drug based on PARP Inhibitor Market Value Comparison by Application (2023-2029) & (US\$ Million)
- Figure 9. Global Cancer Drug based on PARP Inhibitor Market Share by Application in 2022 & 2029
- Figure 10. Ovarian Cancer
- Figure 11. Breast Cancer
- Figure 12. Other
- Figure 13. Global Cancer Drug based on PARP Inhibitor Revenue, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 14. Global Cancer Drug based on PARP Inhibitor Market Size (2018-2029) & (US\$ Million)
- Figure 15. Global Cancer Drug based on PARP Inhibitor Sales (2018-2029) & (K Units)
- Figure 16. Global Cancer Drug based on PARP Inhibitor Average Price (US\$/Unit) & (2018-2029)
- Figure 17. Cancer Drug based on PARP Inhibitor Report Years Considered
- Figure 18. Cancer Drug based on PARP Inhibitor Sales Share by Manufacturers in 2022
- Figure 19. Global Cancer Drug based on PARP Inhibitor Revenue Share by Manufacturers in 2022
- Figure 20. The Global 5 and 10 Largest Cancer Drug based on PARP Inhibitor Players: Market Share by Revenue in 2022
- Figure 21. Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
- Figure 22. Global Cancer Drug based on PARP Inhibitor Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Figure 23. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2029)

Figure 24. North America Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2029)

Figure 25. United States Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 26. Canada Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 27. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2029)

Figure 28. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2029)

Figure 29. Germany Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 30. France Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 31. U.K. Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 32. Italy Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 33. Russia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 34. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2018-2029)

Figure 35. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2018-2029)

Figure 36. China Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 37. Japan Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 38. South Korea Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 39. India Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 40. Australia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 41. China Taiwan Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 42. Indonesia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 43. Thailand Cancer Drug based on PARP Inhibitor Revenue Growth Rate

(2018-2029) & (US\$ Million)

Figure 44. Malaysia Cancer Drug based on PARP Inhibitor Revenue Growth Rate

(2018-2029) & (US\$ Million)

Figure 45. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2029)

Figure 46. Latin America Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2029)

Figure 47. Mexico Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 48. Brazil Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 49. Argentina Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 50. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2029)

Figure 51. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2029)

Figure 52. Turkey Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 53. Saudi Arabia Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 54. UAE Cancer Drug based on PARP Inhibitor Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 55. Global Sales Market Share of Cancer Drug based on PARP Inhibitor by Type (2018-2029)

Figure 56. Global Revenue Market Share of Cancer Drug based on PARP Inhibitor by Type (2018-2029)

Figure 57. Global Cancer Drug based on PARP Inhibitor Price (US\$/Unit) by Type (2018-2029)

Figure 58. Global Sales Market Share of Cancer Drug based on PARP Inhibitor by Application (2018-2029)

Figure 59. Global Revenue Market Share of Cancer Drug based on PARP Inhibitor by Application (2018-2029)

Figure 60. Global Cancer Drug based on PARP Inhibitor Price (US\$/Unit) by Application (2018-2029)

Figure 61. Cancer Drug based on PARP Inhibitor Value Chain

Figure 62. Cancer Drug based on PARP Inhibitor Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

## I would like to order

Product name: Global Cancer Drug based on PARP Inhibitor Market Research Report 2023

Product link: <https://marketpublishers.com/r/G92852892FE0EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G92852892FE0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970